Clinically Important Improvements and Disease Stability with Fluticasone Furoate/Umeclidinium/Vilanterol Once-Daily Single-Inhaler Triple Therapy in the ELLITHE Trial: A Post Hoc Responder Analysis

Clinically Important Improvements and Disease Stability with Fluticasone Furoate/Umeclidinium/Vilanterol Once-Daily Single-Inhaler Triple Therapy in the ELLITHE Trial: A Post Hoc Responder Analysis

Abstract Introduction Responder analyses provide information about characteristics associated with therapeutic benefits. Short-term responses may predict long-term benefits. We evaluated responders, clinically important improvement (CII), disease stability (DS), and the relation of short- to long-te...

Full description

Saved in:
Bibliographic Details
Main Authors: Kai-Michael Beeh, Karl Scheithe, Heike Schmutzler, Saskia Krüger
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-07-01
Series:Pulmonary Therapy
Subjects:
COPD
CAT score
Disease stability
Exacerbation
Lung function
Real-world evidence
Online Access:https://doi.org/10.1007/s41030-025-00306-1
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s41030-025-00306-1

Similar Items